Researchers supported in part by MDA are seeking people with Charcot-Marie-Tooth disease (CMT) to participate in a study to identify genetic modifiers of the type 1A form of CMT (CMT1A) and determine previously unknown genetic causes of CMT.
The study is based at Wayne State University in Detroit, under principal investigator and MDA grantee Michael Shy, with additional U.S. sites in Baltimore; Rochester, N.Y.; Philadelphia; Seattle; and international sites in Australia and London.
MDA and the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH), have partnered to support this large-scale effort.
The study has two components. Prospective participants in the Genetic Modifiers of CMT1A component must:
Prospective participants in the New Causes of CMT component of the study, also known as the CMT Exome Project, must:
The investigators also are seeking people without CMT who are at least 13 years old to serve as controls, meaning they will be compared to those with CMT.
Contact the study coordinators listed below for additional information and registration.
|
Maryland Johns Hopkins University, Baltimore Michigan Wayne State University, Detroit New York University of Rochester Pennsylvania Children's Hospital of Philadelphia |
University of Pennsylvania, Philadelphia Washington University of Washington, Seattle
Australia The Children's Hospital at Westmead United Kingdom National Hospital for Neurology and Neurosurgery, London |
For more details, see Genetics of Charcot-Marie-Tooth (CMT). You also can access this study by entering its number — NCT01193088 — into the search box at ClinicalTrials.gov.
For more information on CMT, see In Focus: Charcot-Marie-Tooth Disease: Streamlined diagnostic procedures, better data collection, a new clinical trials network and new laboratory research are the foundations of MDA's CMT program.